AMG to Present at the 2017 Goldman Sachs U.S. Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
137
AMG to Present at the 2017 Goldman Sachs U.S. Financial Services Conference

WEST PALM BEACH, Fla., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Sean M. Healey, Chairman and Chief Executive Officer of Affiliated Managers Group, Inc. (NYSE: AMG ), and Jay C. Horgen, Chief Financial Officer of AMG, are expected to speak at the 2017 Goldman Sachs U.S. Financial Services Conference in New York on Wednesday, December 6, 2017 at 2:00 p.m. Eastern time.

AMG will provide a live audio transmission of the comments through its website at www.amg.com/InvestorRelations. A replay of the webcast will also be available through AMG’s website shortly after the conclusion of management’s remarks.

About AMG

AMG is a global asset management company with equity investments in leading boutique investment management firms. AMG’s innovative partnership approach allows each Affiliate’s management team to own significant equity in their firm while maintaining operational autonomy. AMG’s strategy is to generate shareholder value through the growth of existing Affiliates, as well as through investments in new Affiliates and additional investments in existing Affiliates. In addition, AMG provides centralized assistance to its Affiliates in strategic matters, marketing, distribution, product development and operations. As of September 30, 2017, AMG’s aggregate assets under management were approximately $804 billion in more than 550 investment products across a broad range of active, return-oriented strategies. For more information, please visit the Company’s website at www.amg.com .

Investor and Media Relations: Alexandra Lynn 
  Selene Oh
  +1 (617) 747-3300
  ir@amg.com
  pr@amg.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading